Unique ID issued by UMIN | UMIN000023243 |
---|---|
Receipt number | R000026431 |
Scientific Title | Comparison of the efficacy of sitagliptin 25mg and teneligliptin 20mg in patient with type2 diabetes and chronic kidney disease. |
Date of disclosure of the study information | 2016/07/20 |
Last modified on | 2025/03/06 19:25:53 |
Comparison of the efficacy of sitagliptin 25mg and teneligliptin 20mg in patient with type2 diabetes and chronic kidney disease.
Comparison of the efficacy of sitagliptin 25mg and teneligliptin 20mg in patient with type2 diabetes and chronic kidney disease.
Comparison of the efficacy of sitagliptin 25mg and teneligliptin 20mg in patient with type2 diabetes and chronic kidney disease.
Comparison of the efficacy of sitagliptin 25mg and teneligliptin 20mg in patient with type2 diabetes and chronic kidney disease.
Japan |
type2 diabetes meliitus
Endocrinology and Metabolism |
Others
NO
Comparison of the efficacy of sitagliptin 25mg and teneligliptin 20mg in patients with CKD and type 2 diabetes
Efficacy
Changes in blood glucose and HbA1c
Interventional
Cross-over
Randomized
Individual
Single blind -participants are blinded
Active
2
Treatment
Medicine |
Distribution to a group as administration of sitagliptin 25mg for three months, followed by administration of teneligliptin 20mg for three months
Distribution to a group as administration of teneligliptin 20mg for three months, followed by administration of sitagliptin 25mg for three months
20 | years-old | <= |
100 | years-old | > |
Male and Female
adult type 2 diabetes patients
Patients with renal function of eGFR 30~50ml/min/1.73m2, in oral teneligliptin 20mg
non insulin dependent state patients
patient's HbA1c are from 6 to 8 percent
Patients of both drugs is contraindicated
Pregnancy, patients in nursing
Patients suffering from a severe disease requiring hospitalization
Patients with anemia (Hb <10g / dl)
Patients undergoing steroid therapy
Patients attending physician was found to be inappropriate for any reason
30
1st name | YASUO |
Middle name | |
Last name | ZENIMARU |
University of Fukui Hospital
Department of Endocrinology and Metabolism
910-1193
23-3 Shimoaitsuki Matsuoka Eiheiji-cho Yoshida-gun Fukui Japan
0776-61-3111
zenimaru@u-fukui.ac.jp
1st name | YASUO |
Middle name | |
Last name | ZENIMARU |
University of Fukui Hospital
Department of Endocrinology and Metabolism
910-1193
23-3 Shimoaitsuki Matsuoka Eiheiji-cho Yoshida-gun Fukui Japan
0776-61-3111
zenimaru@u-fukui.ac.jp
Department of Endocrinology and Metabolism University of Fukui Hospital
N/A
Other
Certified Review Board, University of Fukui
23-3 Shimoaitsuki Matsuoka Eiheiji-cho Yoshida-gun Fukui Japan
0776-61-8758
tokutei@ml.u-fukui.ac.jp
NO
2016 | Year | 07 | Month | 20 | Day |
n.a.
Published
n.a.
22
The hypoglycemic effect obtained with 25 mg of sitagliptin was non-inferior to that of 20 mg of teneligliptin
2025 | Year | 03 | Month | 06 | Day |
Participants were randomly assigned to two groups for the crossover study: the S group, which was first treated with T for 3 months and then switched to sitagliptin 25 mg (S) for 3 months, and the T group, which was treated with S for 3 months and then treated with T for 3 months.
Twelve patients were assigned to the sitagliptin group and 10 to the teneligliptin group, and all completed the study.
none in particular
HbA1c
Completed
2016 | Year | 04 | Month | 25 | Day |
2016 | Year | 04 | Month | 25 | Day |
2016 | Year | 05 | Month | 02 | Day |
2018 | Year | 03 | Month | 31 | Day |
2016 | Year | 07 | Month | 20 | Day |
2025 | Year | 03 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026431